Previous 10 | Next 10 |
2023-03-21 10:03:51 ET Gainers: ImmunityBio ( IBRX ) +21% . NuCana ( NCNA ) +16% . Seres Therapeutics ( MCRB ) +14% . SCYNEXIS ( SCYX ) +13% . Corbus Pharmaceuticals ( CRBP ) +12% . Losers: Altimmune ( ALT ) ...
Gainers: Reata Pharmaceuticals ( RETA ) +175% . OncoSec Medical ( ONCS ) +94% . B&G Foods ( BGS ) +30% . Nerdy ( NRDY ) +29% . SCYNEXIS ( SCYX ) +29% . Blackboxstocks ( BLBX ) +29% . Red Robin Gourmet Burgers ( RRGB ...
Scynexis ( NASDAQ: SCYX ) jumped ~23% in the morning hours Wednesday, marking the sharpest intraday gain since Nov. 2021 after Guggenheim launched its coverage with a Buy rating and an $8 per share target citing the potential of its antifungal treatment Brexafemme. In December, th...
Summary Scynexis has performed terribly during 2022 due to continued disappointment in earnings and sales ramp. New labels, including black-boxed warnings, could further hamper the slow commercial adoption of VVC indication, especially in the retail setting. We do not believe rVVC w...
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. Approval is based on pivotal Phase 3 CANDLE data demonstrating statistically significant supe...
Researchers to study the potential of SCY-247 to fight Candida auris (C.auris) , a multidrug-resistant pathogen named as an “urgent threat” by the Centers for Disease Control (CDC) and included in the “critital priority group” on the World Health Organization (WHO)...
BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species , including Candida auris, and Aspergillus species. Ibrexafungerp, a first-in-class, broad-spectrum oral/IV a...
SCYNEXIS, Inc. (SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr. Marco Taglietti - President & CEO Dr. David Angulo - Chief Medical Officer Ivor Macleod - Chief Financial...
SCYNEXIS press release ( NASDAQ: SCYX ): Q3 GAAP EPS of -$0.62 misses by $0.12 . Revenue of $1.56M (+200.0% Y/Y) misses by $0.5M . Cash, cash equivalents and short-term investments totaled $96.1 million on September 30, 2022, compared to $104.5 million in cash ...
SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications. Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer. Marco Taglietti, M.D., t...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...